IFNG and neoplasm: There is an unmet clinical need for novel therapeutic interventions beyond ICI able to rescue lymphocyte homing and dysfunction in the tumor microenvironment (TME) and to overcome the mechanisms of ICI resistance such as the dysregulation of interferon gamma (IFNγ) signaling, poor major histocompatibility complex I (MHC-I) expression, or defects in antigen processing and presentation (APM).